Serum Neurofilament Light Chain Levels in Parkinson’s Disease Therapy: Preliminary Results from a Phase 2 Clinical Trial of Allogenic Bone Marrow-derived Mesenchymal Stem Cell (S37.006)
To establish the impact of Allogenic Bone Marrow-derived Mesenchymal Stem Cells (allo-hMSCs) on serum Neurofilament Light Chain (NfL) in Parkinson’s disease (PD)
Authors
- Timothy M. Ellmore (ORCID: https://orcid.org/0000-0001-6125-0044)
- Mya C. Schiess (ORCID: https://orcid.org/0000-0001-9348-2587)
- Tran Le (ORCID: https://orcid.org/0000-0002-0030-2266)
- Emily Tharp (ORCID: https://orcid.org/0009-0006-7371-8680)
- Juan Martinez Lemus
- Robert C. Ritter
- Chiamaka Onuigbo
Institutions
- City College of New York (US)
- City University of New York (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211403
- Citations
- 1
- Primary Topic
- Pluripotent Stem Cells Research
- Type
- article
- Field-Weighted Citation Impact
- 0.81